ALIVUS — Alivus Life Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual income statement for Alivus Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	18,852	21,232	21,612	22,832	23,869
Cost of Revenue
Gross Profit	9,797	10,803	11,471	12,812	13,060
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	13,231	15,440	15,605	16,611	17,649
Operating Profit	5,621	5,792	6,008	6,221	6,220
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,709	5,649	6,286	6,313	6,541
Provision for Income Taxes
Net Income After Taxes	3,516	4,187	4,670	4,709	4,856
Net Income Before Extraordinary Items
Net Income	3,516	4,187	4,670	4,709	4,856
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,516	4,187	4,670	4,709	4,856
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	28.7	35.7	38.1	38.4	39.5
Dividends per Share